Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.

Autor: Dörner T; Dept. Med./Rheumatology and Clinical Immunology, Charite Univ. Hospital, Berlin, Germany thomas.doerner@charite.de., Kaul M; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Independent consultant, Neustadt, Germany., Szántó A; Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Tseng JC; Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan., Papas AS; Oral Medicine, Tufts University School of Dental Medicine, Boston, Massachusetts, USA., Pylvaenaeinen I; Early Development Analytics, Novartis Pharmaceutical AG, Basel, Switzerland., Hanser M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Abdallah N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Grioni A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Santos Da Costa A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ferrero E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Gergely P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hillenbrand R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Avrameas A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Cenni B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Siegel RM; Novartis Institutes for BioMedical Research, Basel, Switzerland.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Feb 15; Vol. 83 (3), pp. 360-371. Date of Electronic Publication: 2024 Feb 15.

Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response.

Autor: Gimeno R; Laboratory of Immunology, Department of Pathology, Hospital del Mar, Barcelona, Spain.; Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Ribas-Llauradó C; Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Pesque D; Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain., Andrades E; Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain., Cenni B; Department of Research, BC Novartis Institutes for BioMedical Research, Novartis, Basel, Switzerland., Ambros B; Department of Clinical Development, BA Global Drug Development, Novartis, Basel, Switzerland., Pujol R; Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain., Giménez-Arnau AM; Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.

Publikováno v: Clinical and translational allergy [Clin Transl Allergy] 2023 Mar; Vol. 13 (3), pp. e12227.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.

Autor: Kaul M; Novartis Institutes for Biomedical Research, Basel, Switzerland., End P; Novartis Institutes for Biomedical Research, Basel, Switzerland., Cabanski M; Novartis Institutes for Biomedical Research, Basel, Switzerland., Schuhler C; GCE Solutions, Basel, Switzerland., Jakab A; Novartis Institutes for Biomedical Research, Basel, Switzerland., Kistowska M; Novartis Institutes for Biomedical Research, Basel, Switzerland., Kinhikar A; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA., Maiolica A; Novartis Institutes for Biomedical Research, Basel, Switzerland., Sinn A; Early Phase Clinical Unit, Parexel International, Berlin, Germany., Fuhr R; Early Phase Clinical Unit, Parexel International, Berlin, Germany., Cenni B; Novartis Institutes for Biomedical Research, Basel, Switzerland.

Publikováno v: Clinical and translational science [Clin Transl Sci] 2021 Sep; Vol. 14 (5), pp. 1756-1768. Date of Electronic Publication: 2021 Apr 09.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.